Skip to main
CMPS

COMPASS Pathways (CMPS) Stock Forecast & Price Target

COMPASS Pathways (CMPS) Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Compass Pathways is poised for success in the mental health biotech market, with a strong pipeline and potential for high sales and partnerships. However, risks such as navigating regulatory pathways and maintaining exclusivity could affect the company's future performance. The company's positive clinical results and interest from treatment centers for their new drug are promising signs, but the success of COMP360 is not guaranteed. Adequate risk assessment and strategic partnerships will be crucial for CMPS's success in the competitive mental health market.

Bears say

Compass Pathways is focused on developing therapies for mental health conditions, but despite its optimistic outlook and healthy financials, there are multiple factors that could impact the company's success. The potential for failure in additional indications, such as PTSD, or an inability to commercialize their product could result in significant downside for the company. While there are some key positives, such as strong data in clinical trials and a potential for explosive publicity, there is still uncertainty around the launch and long-term success of the drug. Additionally, with only one product in its portfolio, there is a risk of competition arising in the future. These factors, coupled with the fact that the stock is currently overvalued, contribute to a negative outlook on Compass Pathways.

COMPASS Pathways (CMPS) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About COMPASS Pathways (CMPS) Forecast

Analysts have given COMPASS Pathways (CMPS) a Strong Buy based on their latest research and market trends.

According to 8 analysts, COMPASS Pathways (CMPS) has a Strong Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

COMPASS Pathways (CMPS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.